Testicular cancer: An oncological success story

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Testicular cancer has become a model for a curable neoplasm. Our studies with cisplatin combination chemotherapy allow us to conclude that: (a) short- duration intensive induction therapy with the most active agents in optimal dosage is more important than maintenance therapy; ((b) modest dose escalation increases toxicity without improving therapeutic efficacy; (c) it is possible to develop curative salvage therapy for refractory germ cell tumors; and (d) preclinical models predicting synergism, such as vinblastine + bleomycin or cisplatin + etoposide have clinical relevance. Finally, testicular cancer has also become a model for new drug development. Cisplatin was approved by the Food and Drug Administration for testis and ovarian cancer, and etoposide and ifosfamide were approved for refractory germ cell tumors. The success of these studies confirms the importance of the continued search for new investigational drugs in all solid tumors.

Original languageEnglish
Pages (from-to)2630-2632
Number of pages3
JournalClinical Cancer Research
Volume3
Issue number12 II
StatePublished - Dec 1997

Fingerprint

Testicular Neoplasms
Cisplatin
Germ Cell and Embryonal Neoplasms
Etoposide
Investigational Drugs
Salvage Therapy
Ifosfamide
Vinblastine
Bleomycin
United States Food and Drug Administration
Combination Drug Therapy
Ovarian Neoplasms
Neoplasms
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Testicular cancer : An oncological success story. / Einhorn, Lawrence.

In: Clinical Cancer Research, Vol. 3, No. 12 II, 12.1997, p. 2630-2632.

Research output: Contribution to journalArticle

@article{c2e29c592cba45d8a65f3416cd5411e3,
title = "Testicular cancer: An oncological success story",
abstract = "Testicular cancer has become a model for a curable neoplasm. Our studies with cisplatin combination chemotherapy allow us to conclude that: (a) short- duration intensive induction therapy with the most active agents in optimal dosage is more important than maintenance therapy; ((b) modest dose escalation increases toxicity without improving therapeutic efficacy; (c) it is possible to develop curative salvage therapy for refractory germ cell tumors; and (d) preclinical models predicting synergism, such as vinblastine + bleomycin or cisplatin + etoposide have clinical relevance. Finally, testicular cancer has also become a model for new drug development. Cisplatin was approved by the Food and Drug Administration for testis and ovarian cancer, and etoposide and ifosfamide were approved for refractory germ cell tumors. The success of these studies confirms the importance of the continued search for new investigational drugs in all solid tumors.",
author = "Lawrence Einhorn",
year = "1997",
month = "12",
language = "English",
volume = "3",
pages = "2630--2632",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12 II",

}

TY - JOUR

T1 - Testicular cancer

T2 - An oncological success story

AU - Einhorn, Lawrence

PY - 1997/12

Y1 - 1997/12

N2 - Testicular cancer has become a model for a curable neoplasm. Our studies with cisplatin combination chemotherapy allow us to conclude that: (a) short- duration intensive induction therapy with the most active agents in optimal dosage is more important than maintenance therapy; ((b) modest dose escalation increases toxicity without improving therapeutic efficacy; (c) it is possible to develop curative salvage therapy for refractory germ cell tumors; and (d) preclinical models predicting synergism, such as vinblastine + bleomycin or cisplatin + etoposide have clinical relevance. Finally, testicular cancer has also become a model for new drug development. Cisplatin was approved by the Food and Drug Administration for testis and ovarian cancer, and etoposide and ifosfamide were approved for refractory germ cell tumors. The success of these studies confirms the importance of the continued search for new investigational drugs in all solid tumors.

AB - Testicular cancer has become a model for a curable neoplasm. Our studies with cisplatin combination chemotherapy allow us to conclude that: (a) short- duration intensive induction therapy with the most active agents in optimal dosage is more important than maintenance therapy; ((b) modest dose escalation increases toxicity without improving therapeutic efficacy; (c) it is possible to develop curative salvage therapy for refractory germ cell tumors; and (d) preclinical models predicting synergism, such as vinblastine + bleomycin or cisplatin + etoposide have clinical relevance. Finally, testicular cancer has also become a model for new drug development. Cisplatin was approved by the Food and Drug Administration for testis and ovarian cancer, and etoposide and ifosfamide were approved for refractory germ cell tumors. The success of these studies confirms the importance of the continued search for new investigational drugs in all solid tumors.

UR - http://www.scopus.com/inward/record.url?scp=0031408767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031408767&partnerID=8YFLogxK

M3 - Article

C2 - 10068265

AN - SCOPUS:0031408767

VL - 3

SP - 2630

EP - 2632

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12 II

ER -